1. Introduction {#s0005}
===============

Neuroblastoma, a heterogeneous tumor developed from neural crest progenitor cells, is the most common solid neoplasm of childhood ([@bb0175]). Neuroblastoma takes up nearly 10% of all childhood cancers, yet its proportion of all pediatric oncology deaths is up to 15% ([@bb0025]). Neuroblastoma is characterized by wide clinical course, with some patients having spontaneous regression without chemotherapy or some having poor prognosis despite intense multi-modal therapy ([@bb0165]; [@bb0160]). In general, neuroblastoma cases can be classified into low-, intermediate-, and high-risk groups ([@bb0210]). Nearly 50% of all the neuroblastoma patients are classified into high-risk group, and their survival rates are less than 40% despite intense multi-modal therapy ([@bb0175]). Such unfavorable prognosis was mainly attributed to the extensive metastasis of tumor at the time of diagnosis ([@bb0175]; [@bb0075]).

According to the germline mutations, neuroblastoma is divided into familial and sporadic types. Familial neuroblastoma is rare, with approximately 1--2% of all neuroblastoma cases. The genetic etiology of familial neuroblastoma is relatively elucidated, that is the highly mutations in *PHOX2B* ([@bb0185]; [@bb0005]) or *ALK* gene ([@bb0050]). However, the genetic events predisposing individuals to sporadic neuroblastoma, the most common neuroblastoma, remains unclear. Previous studies indicated that environmental factors such as pregnancy exposures, dwelling condition, and dietary habit are potential risks of sporadic neuroblastoma ([@bb0045]; [@bb0180]; [@bb0190]), yet there still lacks direct linkage evidence. Mounting evidence has suggested that genetic factors also influence the occurrence of neuroblastoma ([@bb0260]; [@bb0275]). For example, common variants of *NEFL* and *CNKN1B* could influence neuroblastoma susceptibility ([@bb0015]; [@bb0020]).

Recent genome-wide association studies (GWASs) have identified genetic variants located in several genes (*HACE1*, *LIN28B*, *BARD1*, *CASC15*, *TP53*, and *LMO1*) associated with neuroblastoma risk by comparing neuroblastoma patients to healthy controls ([@bb0170]; [@bb0010]; [@bb0195]; [@bb0235]; [@bb0055]; [@bb0060]). Moreover, the role of most of these GWAS-identified single nucleotide polymorphisms (SNPs) in neuroblastoma risk have been confirmed in replication case-control studies ([@bb0120]; [@bb0125]; [@bb0270]; [@bb0130]; [@bb0275]). However, these identified genetic variations still account for only a small proportion in predisposing to neuroblastoma.

Therefore, additional gene polymorphisms associated with neuroblastoma susceptibility are needed to be identified. Due to the adoption of the multiple testing correction in the GWAS analysis, some potential SNPs might only have modest risk effects or just be omitted ([@bb0220]). Thus, other research strategies were developed, which include: replication of GWAS-identified SNPs, meta-analysis of GWAS datasets, imputation and epistasis analysis, gene- or pathway-based approaches ([@bb0090]).

In human, DNA repair systems play critical roles in maintaining the stability of cellular functions and genomic integrity ([@bb0245]). The nucleotide excision repair (NER) pathway, one of the DNA repair systems, is responsible for excising bulky DNA lesions ([@bb0095]). The NER pathway includes four steps: damage recognition, DNA unwinding, damage excision, and ligation ([@bb0085]; [@bb0030]). The eight main members of the NER process, *XPA-XPG* and *XP-V*, are all implicated in maintaining genomic integrity ([@bb0035]). The *ERCC1* and *XPF* (also known as *ERCC4*) genes encode proteins that participate in the DNA repair pathways. These two proteins, ERCC1 and XPF, form a heterodimeric complex to cleave the DNA damage on the 5′ side of bubble structures ([@bb0215]; [@bb0080]). Moreover, this complex also functions in the inter-strand crosslink repair ([@bb0240]). Owing to the critical role of ERCC1/XPF complex in maintaining genomic stability, it remains a hot spot of research to explore the role of *ERCC1*/*XPF* genes variations in cancer risks. To date, epidemiological studies declared that *ERCC1*/*XPF* genes polymorphisms were associated with cancer risk at different sites, including colorectal cancer ([@bb0255]), breast cancer ([@bb0250]), gastric cancer ([@bb0110]), and endometrial cancer ([@bb0065]).

However, the genetic variants driving the *ERCC1*/*XPF* genetic association with the risk of neuroblastoma has been evaluated in few instances. To determine whether *ERCC1*/*XPF* genes variations could predispose to neuroblastoma risk or not, we conducted a case-control study in Chinese population.

2. Materials and Methods {#s0010}
========================

2.1. Study Population {#s0015}
---------------------

This study encompassed 393 cases with neuroblastoma and 812 healthy controls of Chinese origin ([@bb0135]; [@bb0280]). Among them, 275 cases were from Guangzhou Women and Children\'s Medical Center and 118 were from The First Affiliated Hospital of Zhengzhou University (**Supplemental Table 1**). At the same time, 531 and 281 controls were recruited from the same district, respectively. Additional details and eligibility criteria for subject selection were reported previously ([@bb0130]). All participants or their guardians provided informed consent before the research. The details of the included subjects have been described in our previous publications ([@bb0115]; [@bb0275]). The study protocols were approved by the Institutional Review Board of Guangzhou Women and Children\'s Medical Center, and The First Affiliated Hospital of Zhengzhou University.

2.2. SNP Selection and Genotyping {#s0020}
---------------------------------

We identified potentially functional SNPs of *ERCC1*/*XPF* genes from dbSNP database (<http://www.ncbi.nlm.nih.gov>/) and an online tool, SNPinfo (<http://snpinfo.niehs.nih.gov>/). Briefly, we searched the potentially functional candidate SNPs located in the 5′- flanking region, 5′ untranslated region, 3′ untranslated region, and exon of *ERCC1*/*XPF* genes. Additional selection criteria were reported in our previous study ([@bb0105]). In final, three SNPs (rs2298881, rs3212986, rs11615) with low linkage disequilibrium in the *ERCC1* gene (**Supplemental Fig. 1**, **Supplemental Table 2**) and one SNP (rs2276466) in the *XPF* gene (**Supplemental Table 3**) met the selection criteria. We used TIANamp Blood DNA Kit (TianGen Biotech Co. Ltd., Beijing, China) to extract genomic DNA from peripheral blood donated by subjects. All the selected SNPs were genotyped on a standard commercial TaqMan real-time PCR, with details reported elsewhere ([@bb0100]; [@bb0150]; [@bb0155]). As a quality control, eight negative controls with water and eight replicate samples were included in each 384-well plate. Moreover, we randomly selected 10% of the samples to a second run. All duplicate sets had a concordance rate of 100%.

2.3. Statistical Analysis {#s0025}
-------------------------

First, we applied goodness-of-fit χ^2^ test to determine whether the selected SNPs among controls were deviated from Hardy-Weinberg equilibrium (HWE). Then we adopted two-sided chi-square test to measure the difference of the demographic variables and allele frequencies between all cases and controls. We also calculated odds ratios (ORs) and 95% confidence intervals (CIs) using logistic regression analysis. All statistical analyses were performed using the version 9.4 SAS software (SAS Institute, Cary, NC). All the *P* values were two sided, and *P* values less than 0.05 considered as significant.

2.4. SNP-gene Expression Correlation Analysis {#s0030}
---------------------------------------------

We performed genotype and mRNA expression correlation analysis, using genotyping data from the HapMap phase II release 23 data set and mRNA expression data by genotypes from EBV-transformed B lymphoblastoid cell lines from the same 270 HapMap individuals ([@bb0105]). We also performed the expression quantitative trait loci (eQTL) analysis using GTEx portal web site (<http://www.gtexportal.org/home/>) to predict potential associations between the SNPs and gene expression levels ([@bb0040]).

3. Results {#s0035}
==========

3.1. *ERCC1* and *XPF* Genes Polymorphisms With Neuroblastoma Susceptibility {#s0040}
----------------------------------------------------------------------------

The detailed characteristics of all the subjects were presented in **Supplemental Table 1** and in our previously published articles ([@bb0135]; [@bb0280]). The distribution of *ERCC1*/*XPF* genes polymorphisms between all cases and controls were listed in [Table 1](#t0005){ref-type="table"}. In analysis of neuroblastoma patients and controls, three SNPs (two in *ERCC1* and one in *XPF*) were associated with neuroblastoma risk: rs2298881 in *ERCC1* (CA vs. AA: adjusted OR = 1.94, 95% CI = 1.30--2.89, *P* = 0.0012; CC vs. AA: adjusted OR = 2.18, 95% CI = 1.45--3.26, *P* = 0.0002); rs11615 in *ERCC1* (AG vs. GG: adjusted OR = 1.31, 95% CI = 1.02--1.69, *P* = 0.038); and rs2276466 in *XPF* (GG vs. CC: adjusted OR = 1.66, 95% CI = 1.02--2.71, *P* = 0.043). However, we failed to detect a statistically significant relationship between rs3212986 in *ERCC1* and neuroblastoma risk. Higher risk of neuroblastoma was found in individuals with 2--3 combined risk genotypes of *ERCC1*, compared with those with 0--1 risk genotypes (adjusted OR = 1.75; 95% CI = 1.25--2.45, *P* = 0.0012).Table 1Logistic regression analysis for the correlation of *ERCC1* and *XPF* polymorphisms with neuroblastoma risk.Table 1GenotypeCases (N = 393)Controls (N = 812)*P*[a](#tf0005){ref-type="table-fn"}Crude OR (95% CI)*P*Adjusted OR (95% CI) [b](#tf0010){ref-type="table-fn"}*P*[b](#tf0010){ref-type="table-fn"}rs2298881 (HWE = 0.060)AA38 (9.67)145 (17.86)1.001.00CA184 (46.82)365 (44.95)**1.92 (1.29--2.87)0.00131.94 (1.30--2.89)0.0012**CC171 (43.51)302 (37.19)**2.16 (1.44--3.23)0.00022.18 (1.45--3.26)0.0002**Additive**0.00071.36 (1.14--1.62)0.00071.36 (1.14--1.62)0.0007**Dominant355 (90.33)667 (82.14)**0.00022.03 (1.39--2.97)0.00032.05 (1.40--2.99)0.0002**Recessive222 (56.49)510 (62.81)**0.0351.30 (1.02--1.66)0.0351.30 (1.02--1.66)0.035**  rs3212986 (HWE = 0.193)CC166 (42.24)372 (45.81)1.001.00CA180 (45.80)343 (42.24)1.18 (0.91--1.52)0.2161.18 (0.91--1.52)0.210AA47 (11.96)97 (11.95)1.09 (0.73--1.61)0.6821.09 (0.73--1.61)0.676Additive0.4651.08 (0.91--1.29)0.3891.08 (0.91--1.29)0.382Dominant227 (57.76)440 (54.19)0.2421.16 (0.91--1.47)0.2421.16 (0.91--1.48)0.236Recessive346 (88.04)715 (88.05)0.9951.00 (0.69--1.45)0.9951.00 (0.69--1.45)0.992  rs11615 (HWE = 0.035)GG209 (53.18)482 (59.36)1.001.00GA155 (39.44)273 (33.62)**1.31 (1.01--1.69)0.0391.31 (1.02--1.69)0.038**AA29 (7.38)57 (7.02)1.17 (0.73--1.89)0.5101.18 (0.73--1.89)0.502Additive0.1141.18 (0.98--1.43)0.0901.18 (0.98--1.43)0.088Dominant184 (46.82)330 (40.64)**0.0421.29 (1.01--1.64)0.0421.29 (1.01--1.64)0.042**Recessive364 (92.62)755 (92.98)0.8201.06 (0.66--1.68)0.8191.06 (0.67--1.68)0.812  rs2276466 (HWE = 0.544)CC230 (59.43)478 (58.87)1.001.00CG125 (32.30)294 (36.21)0.88 (0.68--1.14)0.3370.88 (0.68--1.15)0.345GG32 (8.27)40 (4.93)**1.66 (1.01--2.70)0.0441.66 (1.02--2.71)0.043**Additive**0.049**1.08 (0.88--1.31)0.4591.08 (0.89--1.32)0.452Dominant157 (40.57)334 (41.13)0.8530.98 (0.76--1.25)0.8530.98 (0.77--1.25)0.862Recessive355 (91.73)772 (95.07)**0.0231.74 (1.08--2.82)0.0241.74 (1.08--2.82)0.024**  Combined effect of risk genotypes for *ERCC1*[c](#tf0015){ref-type="table-fn"}038 (9.67)142 (17.49)**0.005**[d](#tf0020){ref-type="table-fn"}1.001.00114 (3.56)28 (3.45)1.87 (0.90--3.90)0.0951.88 (0.90--3.91)0.0932271 (68.96)517 (63.67)**1.96 (1.33--2.88)0.00071.97 (1.34--2.91)0.0006**370 (17.81)125 (15.39)**2.09 (1.32--3.32)0.00172.11 (1.33--3.35)0.0016**  0--152 (13.23)170 (20.94)1.001.002--3341 (86.77)642 (79.06)**0.00121.74 (1.24--2.43)0.00131.75 (1.25--2.45)0.0012**[^2][^3][^4][^5][^6]

3.2. Stratification Analysis {#s0045}
----------------------------

We further evaluated the effects of the selected polymorphisms on the neuroblastoma risk among different strata including age, gender, tumor sites of origin and clinical stages. The conferring increased neuroblastoma risk of rs2298881 variant AC/CC genotypes was more evident in subgroups of age \> 18 months (adjusted OR = 2.26, 95% CI = 1.44--3.56, *P* = 0.0004), female (adjusted OR = 2.15, 95% CI = 1.18--3.92, *P* = 0.012), male (adjusted OR = 1.98, 95% CI = 1.21--3.24, *P* = 0.007), tumor in retroperitoneal (adjusted OR = 4.47, 95% CI = 1.61--12.40, *P* = 0.004), tumor in mediastinum (adjusted OR = 2.37, 95% CI = 1.17--4.81, *P* = 0.017) and clinical stage III + IV (adjusted OR = 2.45, 95% CI = 1.46--4.11, *P* = 0.0007). The rs11615 GA/AA was associated with an increased risk of neuroblastoma, particularly in subgroups of age ≤ 18 (adjusted OR = 1.58, 95% CI = 1.04--2.39, *P* = 0.033), tumor in retroperitoneal (adjusted OR = 1.99, 95% CI = 1.27--3.12, *P* = 0.003), compared with the homozygous wild-type genotype. After combining risk genotypes, we observed that the patients carrying 2--3 risk genotypes had a more evident risk in age \> 18 (adjusted OR = 2.05, 95% CI = 1.36--3.09, *P* = 0.0006), males (adjusted OR = 1.86, 95% CI = 1.19--2.90, *P* = 0.006), tumor in retroperitoneal (adjusted OR = 5.49, 95% CI = 1.98--15.20, *P* = 0.001), clinical stage I + II + 4 s (adjusted OR = 1.65, 95% CI = 1.02--2.68, *P* = 0.041) and clinical stage III + IV (adjusted OR =1.73, 95% CI = 1.13--2.65, *P* = 0.013) ([Table 2](#t0010){ref-type="table"}).Table 2Stratification analysis for the association between *ERCC1* gene genotypes and neuroblastoma susceptibility.Table 2Variablesrs2298881 (case/control)Adjusted OR[a](#tf0025){ref-type="table-fn"} (95% CI)*P*[a](#tf0025){ref-type="table-fn"}rs11615 (case/control)Adjusted OR[a](#tf0025){ref-type="table-fn"} (95% CI)*P*[a](#tf0025){ref-type="table-fn"}Risk genotypes (case/control)Adjusted OR^a^ (95% CI)*P*[a](#tf0025){ref-type="table-fn"}AACA/CCGGGA/AA0--12--3Age, month≤1815/42115/2631.67 (0.83--3.36)0.15161/18265/123**1.58 (1.04--2.39)0.033**17/50109/2551.26 (0.69--2.28)0.450\>1827/103240/404**2.26 (1.44--3.56)0.0004**148/300119/2071.16 (0.86--1.57)0.32735/120232/387**2.05 (1.36--3.09)0.0006**  GenderFemale15/60153/282**2.15 (1.18--3.92)0.012**86/19682/1461.28 (0.88--1.86)0.19222/67146/2751.61 (0.95--2.71)0.076Male23/85202/385**1.98 (1.21--3.24)0.007**123/286102/1841.30 (0.94--1.79)0.11130/103195/367**1.86 (1.19--2.90)0.006**  Sites of originAdrenal gland19/145134/6671.60 (0.96--2.68)0.07490/48263/3301.03 (0.73--1.47)0.85426/170127/6421.35 (0.85--2.13)0.203Retroperitoneal4/14583/667**4.47 (1.61--12.40)0.004**37/48250/330**1.99 (1.27--3.12)0.003**4/17083/642**5.49 (1.98--15.20)0.001**Mediastinum9/145100/667**2.37 (1.17--4.81)0.017**57/48252/3301.32 (0.88--1.97)0.17615/17094/6421.63 (0.92--2.88)0.096Others5/14531/6671.31 (0.50--3.43)0.58721/48215/3301.04 (0.53--2.05)0.9105/17031/6421.60 (0.61--4.19)0.340  Clinical stageI + II + 4 s19/145143/6671.61 (0.97--2.69)0.06790/48272/3301.16 (0.82--1.63)0.39822/170140/642**1.65 (1.02--2.68)0.041**III + IV18/145193/667**2.45 (1.46--4.11)0.0007**110/482101/3301.35 (1.00--1.84)0.05329/170182/642**1.73 (1.13--2.65)0.013**[^7][^8]

*XPF* rs2276466 GG was associated with an increased risk of neuroblastoma, particularly in subgroups of age \> 18 (adjusted OR = 2.21, 95% CI = 1.23--3.97, *P* = 0.008) and females (adjusted OR = 2.51, 95% CI = 1.22--5.16, *P* = 0.013), compared with the CC/CG genotype. However, we failed to observe significant association between *XPF* rs2276466 and neuroblastoma risk under the rest of the evaluated subgroups ([Table 3](#t0015){ref-type="table"}).Table 3Stratification analysis for the association between *XPF* rs2276466 C\>G polymorphism and neuroblastoma susceptibility.Table 3VariablesCC/CGGGCrude OR (95% CI)*P*Adjusted OR[a](#tf0030){ref-type="table-fn"} (95% CI)*P*[a](#tf0030){ref-type="table-fn"}(Cases/controls)Age, month≤18117/2887/171.01 (0.41--2.51)0.9771.01 (0.41--2.51)0.978\>18238/48425/23**2.21 (1.23--3.98)0.0082.21 (1.23--3.97)0.008**  GenderFemales149/32717/15**2.49 (1.21--5.11)0.0132.51 (1.22--5.16)0.013**Males206/44515/251.30 (0.67--2.51)0.4421.32 (0.68--2.56)0.410  Sites of originAdrenal gland143/7729/401.22 (0.58--2.56)0.6091.25 (0.59--2.64)0.558Retroperitoneal75/7727/401.80 (0.78--4.16)0.1681.79 (0.78--4.15)0.172Mediastinum99/77210/401.95 (0.95--4.02)0.0711.97 (0.95--4.06)0.068Others33/7723/401.76 (0.52--5.97)0.3681.71 (0.50--5.82)0.392  Clinical stagesI + II + 4 s149/77213/401.68 (0.88--3.23)0.1161.68 (0.88--3.22)0.118III + IV190/77217/401.73 (0.96--3.11)0.0691.74 (0.96--3.14)0.067[^9][^10]

3.3. Genotype and mRNA Expression Correlation Analysis {#s0050}
------------------------------------------------------

We observed that *ERCC1* mRNA expression levels in rs2298881 CC and AC/CC genotypes carriers were significantly enhanced when compared to the AA genotype carriers in Chinese, Africans, and the overall population ([Table 4](#t0020){ref-type="table"}). We also detected a higher *ERCC1* mRNA expression level for rs3212986 AA genotypes for Europeans (*P* = 0.026) and rs3212986 AC genotype for African (*P* = 0.046). As to the rs2276466 polymorphism in *ERCC4*, the mRNA expression level was upregulated in GG genotype in Europeans (*P* = 0.035) and the overall populations (*P* = 0.021) ([Table 4](#t0020){ref-type="table"}). More specifically, the mRNA expression level of 45 cell lines from Chinese ([Fig. 1](#f0005){ref-type="fig"}a) was similar to that of the overall populations ([Fig. 1](#f0005){ref-type="fig"}b). As a further assessment of the putative functional relevance of *ERCC1* rs2298881 and rs11615, alteration in *ERCC1* expression was seen in transformed fibroblasts tissues of individuals who carry polymorphic allele of *ERCC1* rs2298881 ([Fig. 1](#f0005){ref-type="fig"}c) and rs11615 ([Fig. 1](#f0005){ref-type="fig"}d) based on the public database GTEx portal.Fig. 1Functional implication of *ERCC1* gene rs2298881 and rs11615 polymorphisms. Effect of *ERCC1* gene rs2298881 on mRNA expression in (a) 269 HapMap cell lines of all population and (b) 45 HapMap cell lines of unrelated CHB. The genotype of (c) rs2298881 and (d) rs11615 and expression of *ERCC1* gene in transformed fibroblasts tissues were searched based on the public database GTEx Portal.Fig. 1Table 4*ERCC1* and *XPF* mRNA expression by the genotypes of SNPs, using data from the HapMap[a](#tf0035){ref-type="table-fn"}.Table 4RacemRNA expression (rs2298881)mRNA expression (rs3212986)mRNA expression (rs11615)mRNA expression (rs2276466)GenotypesNo.Mean ± SD*P*[b](#tf0040){ref-type="table-fn"}*P*~trend~[c](#tf0045){ref-type="table-fn"}GenotypesNo.Mean ± SD*P*[b](#tf0040){ref-type="table-fn"}*P*~trend~[c](#tf0045){ref-type="table-fn"}GenotypesNo.Mean ± SD*P*[b](#tf0040){ref-type="table-fn"}*P*~trend~[c](#tf0045){ref-type="table-fn"}GenotypesNo.Mean ± SD*P*[b](#tf0040){ref-type="table-fn"}*P*~trend~[c](#tf0045){ref-type="table-fn"}CHBAA106.68 ± 0.13**0.003**CC206.74 ± 0.130.442[d](#tf0050){ref-type="table-fn"}GG296.73 ± 0.11**0.044**CC286.27 ± 0.090.583[d](#tf0050){ref-type="table-fn"}AC206.76 ± 0.090.053AC196.77 ± 0.090.416AG126.79 ± 0.100.144CG136.23 ± 0.050.126CC156.81 ± 0.08**0.006**AA56.77 ± 0.070.664AA46.83 ± 0.070.111GG36.29 ± 0.060.619AC/CC356.78 ± 0.09**0.006**AC/AA246.77 ± 0.080.377AG/AA166.80 ± 0.090.054CG/GG166.24 ± 0.060.254JPTAA106.76 ± 0.080.242CC316.75 ± 0.090.442[d](#tf0050){ref-type="table-fn"}GG216.75 ± 0.100.872CC216.23 ± 0.070.541AC266.74 ± 0.110.647AC136.77 ± 0.120.442AG226.76 ± 0.100.846CG196.24 ± 0.070.927CC96.81 ± 0.070.118AA0----AA26.76 ± 0.060.976GG56.26 ± 0.120.473AC/CC356.76 ± 0.100.968AC/AA136.77 ± 0.120.442AG/AA246.76 ± 0.100.848CG/GG246.24 ± 0.080.738CEUAA0--0.370CC526.77 ± 0.130.725GG66.85 ± 0.130.447CC546.34 ± 0.080.062[d](#tf0050){ref-type="table-fn"}AC116.74 ± 0.18--AC356.74 ± 0.120.279AG496.76 ± 0.140.168CG286.36 ± 0.110.419CC796.77 ± 0.12--AA36.95 ± 0.04**0.026**AA356.77 ± 0.110.111GG76.42 ± 0.10**0.035**AC/CC906.77 ± 0.13--AC/AA386.76 ± 0.130.620AG/AA846.76 ± 0.130.129CG/GG356.37 ± 0.110.173YRIAA26.61 ± 0.003**\<.0001**[d](#tf0050){ref-type="table-fn"}CC396.77 ± 0.100.208GG876.79 ± 0.100.137CC726.25 ± 0.080.220AC116.71 ± 0.070.066AC456.81 ± 0.09**0.046**AG36.71 ± 0.050.137CG176.28 ± 0.090.194CC766.80 ± 0.09**0.004**AA66.76 ± 0.050.976AA0----GG16.260.850AC/CC876.79 ± 0.09**0.007**AC/AA516.80 ± 0.090.065AG/AA36.71 ± 0.050.137CG/GG186.28 ± 0.090.193AllAA226.71 ± 0.11**\<.0001**[d](#tf0050){ref-type="table-fn"}CC1426.76 ± 0.110.095[d](#tf0050){ref-type="table-fn"}GG1436.78 ± 0.100.599CC1756.28 ± 0.09**0.046**[d](#tf0050){ref-type="table-fn"}AC686.74 ± 0.110.230AC1126.78 ± 0.110.243AG866.76 ± 0.120.385CG776.29 ± 0.110.425CC1796.79 ± 0.10**0.001**AA146.80 ± 0.090.162AA416.77 ± 0.100.793GG166.34 ± 0.12**0.021**AC/CC2476.78 ± 0.11**0.004**AC/AA1266.78 ± 0.100.149AG/AA1276.77 ± 0.120.435CG/GG936.30 ± 0.110.169[^11][^12][^13][^14][^15]

4. Discussion {#s0055}
=============

To determine whether SNPs in *ERCC1*/*XPF* genes can predispose to neuroblastoma risk, we conducted the first case-control, hospital-based study using Chinese children. Our data revealed that the rs2298881 and rs11615 in *ERCC1* as well as rs2276466 in *XPF* exhibited significant positive associations with neuroblastoma risk.

*ERCC1* gene is located to chromosome 19q13.32 and comprises 10 exons. *XPF* is mapped to chromosome 16p13.12 and consists of 11 exons. Their encoded proteins, ERCC1 and XPF, function as a structure-specific endonuclease in a heterodimeric manner ([@bb0230]). This heterodimer catalyzes the 5′ incision during the course of NER ([@bb0145]). In the ERCC1/XPF heterodimer, ERCC1 serves as a critical DNA binding subunit without endonuclease activity, whereas XPF is catalytically active ([@bb0070]). It is elucidated that mutations in the *ERCC1* and *ERCC4* genes are associated with several human inherited disorders ([@bb0200]). The association of the *ERCC1*/*XPF* genes SNPs and cancer risk has been previously reported. For example, individuals carrying the *ERCC1* rs3212986 or rs11615 genotype had a marginally increased risk of colorectal cancer ([@bb0140]). However, in a case-control study conducted in USA, Jennifer et al. failed to provide evidences between the relationship of *ERCC1*/*XPF* genes polymorphisms and endometrial cancer risk ([@bb0065]). The discrepancy results suggested that the same polymorphism might function differently in cancer susceptibility in different ethnicities or different cancer sites. As certain gene SNPs have different roles in certain cancer risk, it is necessary to determine the role of *ERCC1*/*XPF* genes SNPs in neuroblastoma risk.

Herein, we are the first to explore whether *ERCC1*/*XPF* genes SNPs could contribute to the susceptibility of neuroblastoma in Chinese children. The results showed that two SNPs in *ERCC1* (rs2298881 and rs11615) and rs2276466 in *XPF* predisposed to enhanced neuroblastoma risk. These results were quite similar to our previous study, which showed that *ERCC1* rs2298881 and rs11615 variant genotypes were associated with increased gastric cancer risk ([@bb0110]). Such relationships were also observed in many other kinds of cancers in other studies ([@bb0265]).

A myriad of evidence has documented that single SNP in individual gene might not have enough power to impact the risk of overall cancer ([@bb0205]). Somehow, the combination of several SNPs might bring about more significant effects. Therefore, we further performed combination analysis of the effect of risk genotypes. We found an increased risk for neuroblastoma in individuals with 2--3 variant *ERCC1* alleles, compared with those with 0--1 variant alleles, indicating that combinations of variant alleles within NER pathway can exhibit much stronger effect on neuroblastoma risk than the single variant. In agreement with our results, Tse et al., also found that individuals were more likely to develop esophageal adenocarcinoma, if they present with the combined four NER SNPs but not only one variant allele ([@bb0225]). In our previous epidemiological study conducted in other NER genes, we also observed such similar variant-dosage effect ([@bb0115]). In the stratified analysis, we found that the increased neuroblastoma risk of rs2298881 variant AC/CC genotypes was more evident in subgroups of age \> 18 months, female, male, tumor in retroperitoneal, tumor in mediastinum and clinical stage III + IV. Similar results were obtained in rs11615 GA/AA among subgroups of age ≤ 18, tumor in retroperitoneal. We also found that the patients carrying 2--3 risk genotypes had a more evident risk in age \> 18, males, tumor in retroperitoneal, clinical stage I + II + 4 s and clinical stage III + IV. The conflicting results of relationship in subgroups might be attributed to limited statistical power caused by relatively small sample size. The stratification analysis of combined genotypes indicated that the contributing role of the 2--3 risk genotypes in neuroblastoma risk was similar in different clinical stages. We further adopted bioinformatic tools to explore the possible mechanisms for the SNPs showing the most significant associations. The results from HapMap data as well as eQTL analysis suggested that the increased neuroblastoma risk be associated with the upregulated expression levels of *ERCC1* and *XPF* genes. The aberrant expression of *ERCC1* and *XPF* genes might cause decreased NER repair ability, thus increased neuroblastoma risk.

Several limitations accompany with this study. First, the sample size is relative small, especially for the stratification analysis, which will impair the strength of the statistical power. Second, the risk of neuroblastoma cannot be explained only by the SNPs in *ERCC1*/*XPF* genes, other environmental factors also contribute to the risk of neuroblastoma. However, we cannot obtain these factors due to the nature of retrospective investigations. Third, only four SNPs in *ERCC1*/*XPF* genes were chosen for investigation, additional *ERCC1*/*XPF* genes variants contributing to neuroblastoma risk are needed to reveal. Fourth, the results should be interpreted with caution in other populations, as the population source of this study was restricted to unrelated Chinese Han ethnicity.

In summary, here we firstly provide evidence that polymorphisms in *ERCC1*/*XPF* genes could influence neuroblastoma risk. Ongoing epidemiological studies with additional functional analysis as well as with larger samples are needed to further elucidate how genetic variants at NER pathway influence predisposition to neuroblastoma tumorigenesis. Ultimately, our study may provide insight to the role of genetic variations in NER pathway in this aggressive pediatric tumor.
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